Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

DISEASE CHARACTERISTICS:

* Histologically confirmed lymphoproliferative disease

  * CD20-positive disease
* Bidimensionally measurable disease OR abnormal cells detected in blood
* Resistant or refractory to standard therapies and/or unlikely to benefit from additional standard therapies\* AND meets 1 of the following criteria:

  * Disease with anticipated response rate \< 20% after treatment with rituximab alone, including any of the following:

    * Diffuse large cell lymphoma
    * B-cell lymphoblastic lymphoma
    * Burkitt's lymphoma
    * Acute lymphocytic leukemia
  * Relapsed or progressive disease after prior treatment with rituximab, including any of the following:

    * Hodgkin's lymphoma
    * Hairy cell leukemia
    * Chronic lymphocytic leukemia/small lymphocytic lymphoma meeting any of the following criteria:

      * Received prior fludarabine phosphate-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
      * Received prior anti-CD52 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy)
      * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment
    * B-cell prolymphocytic leukemia meeting any of the following criteria:

      * Received prior fludarabine phosphate- or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
      * Received prior anti-CD52 monoclonal antibody therapy OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy)
    * Lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, or follicular lymphoma meeting any of the following criteria:

      * Received prior fludarabine phosphate- and/or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
      * Received prior anti-CD20 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy
      * Received prior radioconjugated anti-CD20 monoclonal antibody therapy OR ineligible to receive such therapy
      * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment
    * Multiple myeloma meeting any of the following criteria:

      * Received prior alkylating agent-, thalidomide-, corticosteroid-, or bortezomib-containing regimens and relapsed after 1 year of treatment OR ineligible to receive such therapies due to comorbidities or allergies
      * Received prior high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy
    * Mantle cell lymphoma meeting the following criteria:

      * Received prior combination chemotherapy and anti-CD20 monoclonal antibody therapy and relapsed after treatment OR ineligible to receive such therapy
    * Diffuse large B-cell lymphoma meeting any of the following criteria:

      * Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
      * Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR not a candidate to receive such therapy
      * Received prior radiolabeled anti-CD20 monoclonal antibody therapy for transformed large cell lymphoma OR ineligible to receive such therapy
    * Burkitt's lymphoma meeting any of the following criteria:

      * Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
      * Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy
    * Lymphomatoid granulomatosis meeting any of the following criteria:

      * Received prior single-agent or combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
      * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment
    * Acute lymphocytic leukemia meeting any of the following criteria:

      * Received prior multi-agent combination chemotherapy administered in sequential induction, consolidation, and maintenance courses and relapsed during or after treatment OR ineligible to receive such therapy
      * Received prior chemotherapy with or without radiotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) and relapsed after treatment OR not a candidate for such therapy
      * Received prior treatment with chemotherapy with or without radiotherapy followed by allogeneic HSCT and relapsed after treatment (or not a candidate for such therapy) AND demonstrates persistent cytogenetic, fluorescent in situ hybridization, or molecular (reverse transcriptase-polymerase chain reaction) evidence of the bcr-abl fusion gene despite 6 weeks of treatment with imatinib mesylate NOTE: \*Not eligible to receive standard available salvage regimens anticipated to result in durable remission
* No active CNS malignancy
* Not considered a candidate for allogeneic HSCT
* HLA-partially matched (≥ 2/6) related donor available

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* Life expectancy \> 3 months
* Not pregnant
* Negative pregnancy test
* Fertile women must use effective contraception
* Bilirubin \< 1.5 times upper limit of normal (ULN)
* AST \< 3.0 times ULN
* Cardiac ejection fraction \> 35%
* Absolute neutrophil count \> 1,000/mm³ (without cytokines)
* Platelet count \> 50,000/mm³ (untransfused)
* No significant organ dysfunction
* No active uncontrolled infections
* No hypersensitivity reaction to rituximab that has precluded completion of a 4-week course of rituximab therapy
* No uncontrolled psychiatric illness or medical condition that would preclude tolerance of study treatment

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Recovered from prior therapy for at least 7 days
* More than 30 days since prior cytotoxic chemotherapy
* At least 14 days since prior steroids
* At least 14 days since prior radiotherapy to non-target lesions